Crosslinked polymer compositions
First Claim
1. A crosslinkable composition comprised of:
- (a) a first crosslinkable component having m nucleophilic groups, wherein m≧
2; and
(b) a second crosslinkable component having n electrophilic groups capable of reaction with the m nucleophilic groups to form covalent bonds,wherein n≧
2 and m+n≧
5, the first component comprises two or more amino acid residues selected from the group consisting of amino acids comprising primary amine groups and amino acids comprising thiol groups, the second component comprises a polyethylene glycol moiety, and each of the first and second crosslinkable components is biocompatible, synthetic, and nonimmunogenic.
13 Assignments
0 Petitions
Accused Products
Abstract
Provided are crosslinked polymer compositions that include a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (—NH2) or thiol (—SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer, which contains or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further include other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents. Also disclosed are methods for using the crosslinked polymer compositions to effect adhesion between a first surface and a second surface; to effect tissue augmentation; to prevent the formation of surgical adhesions; and to coat a surface of a synthetic implant.
-
Citations
69 Claims
-
1. A crosslinkable composition comprised of:
-
(a) a first crosslinkable component having m nucleophilic groups, wherein m≧
2; and(b) a second crosslinkable component having n electrophilic groups capable of reaction with the m nucleophilic groups to form covalent bonds, wherein n≧
2 and m+n≧
5, the first component comprises two or more amino acid residues selected from the group consisting of amino acids comprising primary amine groups and amino acids comprising thiol groups, the second component comprises a polyethylene glycol moiety, and each of the first and second crosslinkable components is biocompatible, synthetic, and nonimmunogenic. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)
-
-
22. A crosslinkable composition comprised of:
-
(a) a first crosslinkable component having m nucleophilic groups, wherein m≧
2; and(b) a second crosslinkable component having n electrophilic groups capable of reaction with the m nucleophilic groups to form covalent bonds, wherein n≧
2 and m+n≧
5, the first component comprises two or more amino acid residues selected from the group consisting of amino acids comprising primary amine groups and amino acids comprising thiol groups, the second component comprises a polyethylene glycol moiety, the electrophilic groups are succinimidyl moieties, and each of the first and second crosslinkable components is biocompatible, synthetic, and nonimmunogenic. - View Dependent Claims (23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)
-
-
43. A crosslinkable composition comprised of:
-
(a) a first crosslinkable component having m nucleophilic groups, wherein m≧
2; and(b) a second crosslinkable component having n electrophilic groups capable of reaction with the m nucleophilic groups to form covalent bonds, wherein n≧
2 and m+n≧
5, the first component comprises two or more amino acid residues selected from the group consisting of amino acids comprising primary amine groups and amino acids comprising thiol groups, the second component comprises a multifunctionally activated polyethylene glycol, and each of the first and second crosslinkable components is biocompatible, synthetic, and nonimmunogenic. - View Dependent Claims (44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)
-
Specification
-
- Resources
-
Current AssigneeAngiotech Pharmaceuticals Incorporated
-
Original AssigneeAngiotech Pharmaceuticals Incorporated
-
InventorsRhee, Woonza M., Berg, Richard A., DeLustro, Frank A.
-
Primary Examiner(s)Nutter, Nathan M.
-
Application NumberUS11/078,254Publication NumberTime in Patent Office649 DaysField of Search525/54.1, 525/419, 525/420, 525/425US Class Current525/54.1CPC Class CodesA61L 2300/232 Monosaccharides, disacchari...A61L 2300/252 Polypeptides, proteins, e.g...A61L 2300/606 CoatingsA61L 24/043 Mixtures of macromolecular ...A61L 24/08 Polysaccharides A61L24/043 ...A61L 27/26 Mixtures of macromolecular ...A61L 27/34 Macromolecular materialsA61L 27/54 Biologically active materia...A61L 31/041 Mixtures of macromolecular ...A61L 31/16 Biologically active materia...C08B 37/0075 Heparin; Heparan sulfate; D...C08G 65/329 with organic compoundsC08H 1/00 Macromolecular products der...C08H 1/06 derived from horn, hoofs, h...C08L 5/16 Cyclodextrin; Derivatives t...C08L 71/00 Compositions of polyethers ...C08L 71/02 Polyalkylene oxidesY10S 623/90 Stent for heart valveY10S 623/901 Method of manufacturing pro...
